The SELECT trial in 2023 showed that semaglutide, a GLP-1 receptor agonist, reduced the risk for cardiovascular events in people with obesity and cardiovascular disease. The trial involved 17,604 adults with preexisting heart disease and overweight or obesity but no diabetes. Semaglutide reduced major adverse cardiovascular events by 20% and had a significant impact on all-cause mortality. The trial opens the door for weight loss as a primary prevention strategy aided by pharmacotherapy, indicating that newer weight-loss drugs should be considered cardiovascular drugs routinely prescribed by cardiologists. Cardiology experts believe this is a game-changer and provides an important tool for reducing cardiovascular risk in high-risk patients.
Source link
The implications of SELECT on CVD prevention in high-risk patients with obesity
